ClinicalTrials.gg
CompletedNCT06514157PUTUOUpdated Aug 26, 2025

Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants.

A Phase 1 interventional study of budesonide/albuterol sulfate metered dose inhaleor (BDA MDI) in Healthy Volunteer, sponsored by AstraZeneca. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A phase I study to assess the PK, safety, and tolerability of budesonide and albuterol delivered from a single dose of BDA MDI administered by inhalation in healthy Chinese participants.

Read the detailed description

This is a Phase I, single centre, single arm, open-label study to gather information on the PK, safety, and tolerability of budesonide and albuterol delivered from BDA MDI after single dose administration in healthy Chinese male and female participants. Approximately 14 healthy Chinese participants, aged 18 to 55 years, will be assigned to study intervention.

The study will comprise:

A screening period of minimum 2 days and maximum 27 days Inpatient admission period during which participants will be resident from the day prior to administration of BDA MDI (Day -1) until at least 24 hours after dosing. Participants will be discharged on the morning of Day 2. The treatment will consist of a single dose of BDA MDI 160 μg/180 μg (administered as 2 actuations of 80 μg/90 μg) followed by 24 hours of plasma sampling for determination of PK parameters A Follow-up Visit within 3 to 7 days after the administration of BDA MDI.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Chinese healthy volunteer
  • Phase I
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be 18 to 55 years of age inclusive, at the time of signing the .
  2. Chinese participants who are healthy
  3. Body weight ≥ 45 kg for female participants and ≥ 50 kg for male participants and body ≤ 26 kg/m2 at Visit 1 (screening).
  4. Male and non-pregnant, non-lactating female.
  5. Provision of signed and dated, written informed consent prior to any study specific procedures.
  6. Resting heart rate ≥ 50 beats per minute (bpm) and ≤ 100 bpm at Visit 1 (screening) and at admission to the unit on Day -1 at Visit 2.
  7. Non-smoker.
  8. Must be able to demonstrate proper inhalation technique using the Vitalograph AIM device 3 repeated times as well as be able to use the BDA MDI according to instructions at Visit 1 (screening) and Day -1.

Exclusion criteria

Exclusion Criteria:

  1. As judged by the investigator, any evidence which in the investigator's opinion makes it undesirable for the participant to participate in the study.
  2. History of any significant drug allergy or to albuterol sulfate or other beta-adrenergic agonists or to budesonide or other .
  3. Recent history of a disease or condition that would result in any residual upper respiratory airways/lung inflammatory process or residual limited lung function at the time of Day 1 at Visit 2.
  4. Have any gastrointestinal, hepatic, or renal condition that might affect the absorption, distribution, biotransformation, or excretion of drugs.
  5. Use of any medication within 2 weeks or within the equivalent time of 5 half-lives of taking the last dose (whichever is longer) before the study intervention, or hormonal drug products and traditional Chinese medicines within 30 days before the study intervention.
  6. Participation in any other clinical investigation using an experimental drug requiring repeated blood or plasma draws within 30 days or 5 half-lives of the drugs (whichever takes longer) of Day 1 at Visit 2.
  7. Have abnormal and results on the physical examination, medical history, clinical chemistry, haematology, or urinalysis at Visit 1 (screening) or Day -1 at Visit 2.
  8. Resting systolic blood pressure ≥ 140 or ≤ 90 mmHg and resting diastolic blood pressure ≥ 90 or ≤ 50 mmHg at Visit 1 (Screening) or Day -1 at Visit 2.
  9. 12-lead showing ≥ 450 msec for participants as indicated in the reading report assessed at Visit 1 (screening).
  10. Positive test results for syphilis antibody, , antibody and/or I antibodies at Visit 1 (screening).
  11. Have a history of alcohol or substance abuse within the previous 5 years as reported by the participant.
  12. Positive results for drugs of abuse at Visit 1 (screening) or Day -1 at Visit 2.
  13. Have participated in a blood/plasma donation or blood loss greater than 400 mL within 90 days, or greater than 200 mL within 30 days prior to screening (Visit 1).
  14. Inability to be venipunctured or tolerate venous access as determined by the PI or designee.
  15. Participants unable to give their consent, or participants of consenting age but under guardianship, or vulnerable participants.
  16. In the opinion of the PI, participants who are unlikely to comply with the protocol requirements, instructions, and study-related restrictions.
  17. Participants who are relatives of the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff or directly involved in the conduct of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    BDA MDI

    Each randomized participant will receive a single dose of BDA MDI 160 μg/180 μg (administered as 2 actuations of 80 μg/90 μg) on Day 1 in the morning.

    Combination Product: budesonide/albuterol sulfate metered dose inhaleor (BDA MDI)

Interventions

  • Combination productbudesonide/albuterol sulfate metered dose inhaleor (BDA MDI)

    BDA MDI 160 μg/180 μg (single dose administered as 2 actuations of 80 μg/90 μg)

06

What researchers measure

Primary outcomes

  1. AUClast of budesonide and albuterol

    To characterize the PK of budesonide and albuterol delivered from BDA MDI after single dose administration

    Time frame: From Day 1 pre-dose to 24 hours post dose

  2. AUCinf of budesonide and albuterol

    To characterize the PK of budesonide and albuterol delivered from BDA MDI after single dose administration

    Time frame: From Day 1 pre-dose to 24 hours post dose

  3. Cmax of budesonide and albuterol

    To characterize the PK of budesonide and albuterol delivered from BDA MDI after single dose administration

    Time frame: From Day 1 pre-dose to 24 hours post dose

  4. tmax of budesonide and albuterol

    To characterize the PK of budesonide and albuterol delivered from BDA MDI after single dose administration

    Time frame: From Day 1 pre-dose to 24 hours post dose

  5. Tlast of budesonide and albuterol

    To characterize the PK of budesonide and albuterol delivered from BDA MDI after single dose administration

    Time frame: From Day 1 pre-dose to 24 hours post dose

  6. t½λz of budesonide and albuterol

    To characterize the PK of budesonide and albuterol delivered from BDA MDI after single dose administration

    Time frame: From Day 1 pre-dose to 24 hours post dose

  7. CL/F of budesonide and albuterol

    To characterize the PK of budesonide and albuterol delivered from BDA MDI after single dose administration

    Time frame: From Day 1 pre-dose to 24 hours post dose

  8. Vz/F of budesonide and albuterol

    To characterize the PK of budesonide and albuterol delivered from BDA MDI after single dose administration

    Time frame: From Day 1 pre-dose to 24 hours post dose

Secondary outcomes

  1. Incidence of AEs/SAEs

    To assess the safety and tolerability of budesonide and albuterol delivered from BDA MDI after single dose administration in healthy Chinese participants

    Time frame: Screening(Day-27 to Day-2), Day-1, Day1(dosing day), Day 2, Follow-Up(Day 3 to Day7)

  2. Incidence of abnormal vital signs: blood pressure and pulse rate

    To assess the safety and tolerability of budesonide and albuterol delivered from BDA MDI after single dose administration in healthy Chinese participants

    Time frame: Screening(Day-27 to Day-2), Day-1, Day1(post dose), Day 2, Follow-Up(Day 3 to Day7)

  3. Incidence of abnormal haematology assessments: WBC count, RBC count, Hemoglobin, Platelets and Leukocytes absolute count

    To assess the safety and tolerability of budesonide and albuterol delivered from BDA MDI after single dose administration in healthy Chinese participants

    Time frame: Screening (Day -27 to Day -2), Day -1, Follow-up (Day 3 to Day 7)

  4. Incidence of abnormal 12-lead ECG parameters: heart rate, RR interval, QRS interval, PR interval, QT/QTcF interval.

    To assess the safety and tolerability of budesonide and albuterol delivered from BDA MDI after single dose administration in healthy Chinese participants

    Time frame: Screening (Day -27 to Day -2), Day 1(post dose), Follow-up (Day 3 to Day 7)

  5. Incidence of abnormal clinical chemistry assessments: Sodium, potassium, calcium, urea, creatinine, ALP, ALT, AST, total bilirubin, CK albumin and fasting glucose

    To assess the safety and tolerability of budesonide and albuterol delivered from BDA MDI after single dose administration in healthy Chinese participants

    Time frame: Screening (Day -27 to Day -2), Day -1, Follow-up (Day 3 to Day 7)

  6. Incidence of abnormal urinalysis: Glucose, blood, protein, microscopy(including RBC,WBC and casts)

    To assess the safety and tolerability of budesonide and albuterol delivered from BDA MDI after single dose administration in healthy Chinese participants

    Time frame: Screening (Day -27 to Day -2), Day -1, Follow-up (Day 3 to Day 7)

07

Study locations

1 site
  • Research Site
    Shanghai, 200031, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Sep 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jul 23, 2024
StartActual
Aug 19, 2024
Primary completionActual
Sep 9, 2024
CompletionActual
Sep 9, 2024
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06514157
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 23, 2024
Start date
Aug 19, 2024
Primary completion
Sep 9, 2024
Completion
Sep 9, 2024
Last update
Aug 26, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion